Literature DB >> 26447782

Design, Synthesis, and Evaluation of Novel Ferroquine and Phenylequine Analogues as Potential Antiplasmodial Agents.

Leon Jacobs1, Carmen de Kock2, Katherine A de Villiers1, Peter J Smith2, Vincent J Smith1, Willem A L van Otterlo1, Margaret A L Blackie3.   

Abstract

7-Chloroquinoline-based antimalarial drugs are effective in the inhibition of hemozoin formation in the food vacuole of the Plasmodium parasite, the causative agent of malaria. We synthesized five series of ferroquine (FQ) and phenylequine (PQ) derivatives, which display good in vitro efficacy toward both the chloroquine-sensitive (CQS) NF54 (IC50 : 4.2 nm) and chloroquine-resistant (CQR) Dd2 (IC50 : 33.7 nm) strains of P. falciparum. Several compounds were found to have good inhibitory activity against β-hematin formation in an NP-40 detergent assay, with IC50 values ranging between 10.4 and 19.2 μm.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  ferroquine; malaria; oxalamide; phenylequine; β-hematin

Mesh:

Substances:

Year:  2015        PMID: 26447782     DOI: 10.1002/cmdc.201500349

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  2 in total

1.  Correlation between anti-malarial and anti-haemozoin activities of anti-malarial compounds.

Authors:  Dao Ngoc Hien Tam; Gehad Mohamed Tawfik; Amr Ehab El-Qushayri; Ghaleb Muhammad Mehyar; Sedralmontaha Istanbuly; Sedighe Karimzadeh; Vo Linh Tu; Ranjit Tiwari; Truong Van Dat; Phuong Thuy Viet Nguyen; Kenji Hirayama; Nguyen Tien Huy
Journal:  Malar J       Date:  2020-08-21       Impact factor: 2.979

2.  Structural basis for substrate recognition and chemical inhibition of oncogenic MAGE ubiquitin ligases.

Authors:  Seung Wook Yang; Xin Huang; Wenwei Lin; Jaeki Min; Darcie J Miller; Anand Mayasundari; Patrick Rodrigues; Elizabeth C Griffith; Clifford T Gee; Lei Li; Wei Li; Richard E Lee; Zoran Rankovic; Taosheng Chen; Patrick Ryan Potts
Journal:  Nat Commun       Date:  2020-10-01       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.